EcoDrugPlus

Lysyl Oxidase-Like 2a

Ensembl ID : ENSOSIG00000001832
Gene Symbol: LOXL2A
1 Cross references
209 Possible Orthologues:

Lysyl Oxidase-Like 2b

Ensembl ID : ENSOSIG00000005166
Gene Symbol: LOXL2B
1 Cross references
209 Possible Orthologues:

Lysyl Oxidase-Like 2b

Ensembl ID : ENSOSIG00000015490
Gene Symbol: LOXL2B
1 Cross references
209 Possible Orthologues:

Macrophage Migration Inhibitory Factor

Ensembl ID : ENSOSIG00000012690
Gene Symbol: MIF
1 Cross references
229 Possible Orthologues:

Matrix Metallopeptidase 14a (Membrane-Inserted)

Ensembl ID : ENSOSIG00000005644
Gene Symbol: MMP14A
1 Cross references
198 Possible Orthologues:

Matrix Metallopeptidase 14b (Membrane-Inserted)

Ensembl ID : ENSOSIG00000003768
Gene Symbol: MMP14B
1 Cross references
196 Possible Orthologues:

Matrix Metallopeptidase 2

Ensembl ID : ENSOSIG00000023506
Gene Symbol: MMP2
1 Cross references
209 Possible Orthologues:

Matrix Metallopeptidase 9

Ensembl ID : ENSOSIG00000021831
Gene Symbol: MMP9
1 Cross references
215 Possible Orthologues:

Mechanistic Target Of Rapamycin Kinase

Ensembl ID : ENSOSIG00000021010
Gene Symbol: MTOR
1 Cross references
183 Possible Orthologues:

Mechanistic Target Of Rapamycin Kinase

Ensembl ID : ENSOSIG00000010246
Gene Symbol: MTOR
1 Cross references
201 Possible Orthologues:

Melanocortin 1 Receptor

Ensembl ID : ENSOSIG00000019258
Gene Symbol: MC1R
1 Cross references
159 Possible Orthologues:

Melanocortin 4 Receptor

Ensembl ID : ENSOSIG00000011371
Gene Symbol: MC4R
1 Cross references
89 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).